RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

NRx Pharmaceuticals (Nasdaq: NRXP) announced the initiation of clinical training for ICU physicians in Georgia on using intravenous ZYESAMI™ (Aviptadil-acetate) for emergency COVID-19 treatment. Additionally, the ongoing phase 2/3 trial for inhaled ZYESAMI™ will be extended to Georgia and potentially neighboring countries. Clinical drug supplies are expected to ship within two weeks. The partnership is partially funded through Relief Therapeutics. ZYESAMI™ aims to address COVID-19-related respiratory failure by targeting cellular mechanisms affected by the virus.

Relief Therapeutics announced the acquisition of APR Applied Pharma Research for CHF 21.5 million in cash and CHF 45 million in shares, with contingent payments based on milestones. This acquisition aims to diversify Relief's pipeline with commercial and clinical-stage products, enhancing its infrastructure for future launches. Relief gains access to APR's R&D expertise, which includes the marketed product Golike for PKU and the promising APR-TD011 for epidermolysis bullosa. The deal is viewed as a significant step in Relief's transformation into a robust commercial-stage biopharmaceutical firm.

Relief Therapeutics Holding AG held its Annual General Meeting (AGM) on June 20, 2021, where all agenda items were approved by over 90% of represented votes. The meeting, conducted virtually due to COVID-19, saw participation equivalent to 41.54% of total outstanding shares. Key outcomes include the approval of the 2020 financial statements, a CHF 20,009,867 loss carryforward, and increases in authorized and conditional share capital. New board members Dr. Patrice Jean and Paolo Galfetti were elected to aid in the company’s growth strategy, focusing on the development of RLF-100 and other business opportunities.

Relief Therapeutics Holding AG (OTCQB: RLFTF) reported on June 16, 2021, that its collaboration partner, NRx Pharmaceuticals, announced results from the U.S. Expanded Access Protocol (EAP) for the drug RLF-100 (aviptadil). The EAP involved 240 ICU patients with critical COVID-19 respiratory failure. NRx intends to submit these findings as "real world" evidence to the FDA, supporting earlier clinical trial results. Relief focuses on clinical-stage programs, with RLF-100 in late-stage development for COVID-19 and a collaboration for the treatment of Urea Cycle Disorders.

Relief Therapeutics Holding AG (OTCQB: RLFTF) has announced that NRx Pharmaceuticals submitted an application to the FDA for Emergency Use Authorization (EUA) for its drug aviptadil to treat critical COVID-19 patients with respiratory failure. The EUA submission is based on a successful phase 2b/3 clinical trial in the U.S. Relief anticipates the decision from the FDA and is optimistic about the drug's potential to provide effective treatment options. The company also acknowledges NRx's recent Nasdaq listing and aims to advance aviptadil's development in Europe.

NRx Pharmaceuticals (Nasdaq: NRXP) has applied for Emergency Use Authorization (EUA) from the FDA for its drug, ZYESAMI™ (Aviptadil-acetate), aimed at treating critically ill COVID-19 patients with respiratory failure.

The study revealed a significant improvement in patient survival and reduced hospital stays compared to a placebo. Enrolled were 196 participants, and the findings support ZYESAMI™ as the first medication showing effectiveness for patients in advanced stages of COVID-19. The clinical trial had positive implications for patient recovery despite prior treatments.

Relief Therapeutics has appointed Dr. Taneli Jouhikainen as its new Chief Operating Officer, effective June 1, 2021. This newly created role aims to support the company’s transition from a clinical-stage entity to a diversified product-driven firm. Dr. Jouhikainen brings over 25 years of life sciences experience, having held significant positions in various biopharmaceutical companies. His responsibilities include overseeing product development and integration of new activities to bolster Relief’s growth strategy.

Relief Therapeutics Holding AG has announced its Annual General Meeting (AGM) to be held on June 18, 2021, due to the COVID-19 pandemic, shareholders will participate virtually. Key agenda items include the approval of the Annual Report and financial statements for 2020, discharge of the Board and Executive Committee, and proposals to increase authorized and conditional share capital. Notably, a loss of CHF 20,009,867 for 2020 was reported, with proposed limits on compensation for Board and Executive members unchanged from 2020.

Relief Therapeutics provided an update on ACER-001, a powder formulation of sodium phenylbutyrate for treating urea cycle disorders (UCDs). The company announced a Type B pre-NDA meeting with the FDA, aiming for an NDA submission in mid-2021. In Europe, Relief plans to engage with the European Medicines Agency regarding a Marketing Authorization Application later in 2021. If successful, ACER-001 could launch in both regions in 2022, targeting UCDs and Maple Syrup Urine Disease. Relief emphasizes the urgent need for better treatment options for UCD patients.